BidaskClub Downgrades Kura Oncology (NASDAQ:KURA) to Buy

Kura Oncology (NASDAQ:KURA) was downgraded by equities researchers at BidaskClub from a “strong-buy” rating to a “buy” rating in a research report issued on Friday, March 16th.

Several other equities research analysts have also recently commented on the stock. Cann reaffirmed a “buy” rating and issued a $30.00 target price on shares of Kura Oncology in a research report on Friday, February 16th. Citigroup set a $28.00 price target on shares of Kura Oncology and gave the company a “buy” rating in a research report on Friday, February 16th. Zacks Investment Research cut shares of Kura Oncology from a “hold” rating to a “sell” rating in a research report on Wednesday, January 10th. Wedbush started coverage on shares of Kura Oncology in a research report on Tuesday, December 26th. They set a “buy” rating and a $19.00 price target for the company. Finally, Oppenheimer set a $18.00 price target on shares of Kura Oncology and gave the company a “buy” rating in a research report on Monday, December 11th. Three analysts have rated the stock with a hold rating and six have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $22.00.

How to Become a New Pot Stock Millionaire

Shares of NASDAQ:KURA traded down $0.95 on Friday, hitting $16.70. The company had a trading volume of 258,821 shares, compared to its average volume of 345,009. Kura Oncology has a 1 year low of $5.90 and a 1 year high of $24.02. The company has a current ratio of 9.44, a quick ratio of 9.44 and a debt-to-equity ratio of 0.07. The stock has a market cap of $588.70, a price-to-earnings ratio of -10.99 and a beta of 4.21.

Kura Oncology (NASDAQ:KURA) last posted its earnings results on Monday, March 12th. The company reported ($0.37) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.36) by ($0.01). equities analysts forecast that Kura Oncology will post -1.43 EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. BlackRock Inc. lifted its position in Kura Oncology by 49.1% during the 4th quarter. BlackRock Inc. now owns 1,524,817 shares of the company’s stock valued at $23,331,000 after acquiring an additional 502,296 shares during the period. Nexthera Capital LP increased its stake in Kura Oncology by 72.3% during the 4th quarter. Nexthera Capital LP now owns 445,550 shares of the company’s stock valued at $6,817,000 after purchasing an additional 187,034 shares in the last quarter. Vanguard Group Inc. increased its stake in Kura Oncology by 13.0% during the 2nd quarter. Vanguard Group Inc. now owns 433,868 shares of the company’s stock valued at $4,035,000 after purchasing an additional 50,033 shares in the last quarter. Millennium Management LLC increased its stake in Kura Oncology by 35.7% during the 4th quarter. Millennium Management LLC now owns 303,905 shares of the company’s stock valued at $4,650,000 after purchasing an additional 79,989 shares in the last quarter. Finally, EAM Investors LLC bought a new stake in Kura Oncology during the 3rd quarter valued at about $2,884,000. 58.56% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: This news story was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this news story on another domain, it was illegally copied and reposted in violation of US & international trademark and copyright law. The legal version of this news story can be accessed at https://www.dispatchtribunal.com/2018/04/07/kura-oncology-kura-downgraded-by-bidaskclub-to-buy.html.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancers. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.

Analyst Recommendations for Kura Oncology (NASDAQ:KURA)

Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply